Glasgow collaborators visit new Heptares Therapeutics site
Dr Sarah Mancini, Prof Graeme Milligan and Prof Andrew Tobin recently visited the new site of Heptares Therapeutics in Granta Park, Cambridge.
Sarah is a PDRA funded by the clinical-stage company which uses proprietary StaR® technology and structure-based drug design capabilities to create novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases.
The visit involved a meeting to discuss the progress of the ORBIT (Opportunities in Receptor Biology for Industrial Translation) collaboration, and provided Sarah with the opportunity to present her work to the molecular pharmacology group there. Sarah, Graeme and Andrew were also treated to a tour of the company’s new facilities ahead of Sarah’s upcoming visit there to do some research.
First published: 10 October 2018